‘It’s a vote for hope’: first gene therapy for muscular dystrophy nears approval, but will it work?
By Sara Reardon,
Nature
| 06. 02. 2023
The road to gene therapies for genetic disorders has been long — and expensive — but the field could soon get some good news. On 22 June, the US Food and Drug Administration will decide whether to grant a fast-track approval to the first gene therapy for Duchenne muscular dystrophy (DMD), a genetic disorder that affects around 1 in 3,500 boys. Children with DMD can’t make a protein called dystrophin, resulting in progressive muscle degeneration and death in their twenties due to heart or respiratory failure.
The therapy, known as SRP-9001, is made by Sarepta Therapeutics based in Cambridge, Massachusetts. It would be the 13th gene therapy that the FDA has approved since 2017, and the first to target a prevalent genetic disease in children. The accelerated approval would allow the drug to reach the market before large clinical trials have been completed, on the basis of evidence that the therapy allows boys to make an engineered form of dystrophin.
The decision date was delayed late in May after FDA officials and advisers raised concerns about the strength of Sarepta’s...
Related Articles
By Mary Annette Pember, ICT News [cites CGS' Katie Hasson] | 04.18.2025
The sight of a room full of human cadavers can be off-putting for some, but not for Haley Omeasoo.
In fact, Omeasoo’s comfort level and lack of squeamishness convinced her to pursue studies in forensics and how DNA can be...
Gray wolf by Jessica Eirich via Unsplash
“I’m not a scarcity guy, I’m an abundance guy”
– Colossal co-founder and CEO Ben Lamm, The New Yorker, 4/14/25
Even the most casual consumers of news will have seen the run of recent headlines featuring the company Colossal Biosciences. On March 4, they announced with great fanfare the world’s first-ever woolly mice, as a first step toward creating a woolly mammoth. Then they topped that on April 7 by unveiling one...
By Katrina Northrop, The Washington Post | 04.06.2025
photo via Wikimedia Commons licensed under CC by 3.0
China's most infamous scientist is attempting a comeback. He Jiankui, who went to jail for three years after claiming he had created the world's first genetically altered babies, says he remains...
By Anumita Kaur [cites CGS’ Katie Hasson], The Washington Post | 03.25.2025
Genetic information company 23andMe has said that it is headed to bankruptcy court, raising questions for what happens to the DNA shared by millions of people with the company via saliva test kits.
Sunday’s announcement clears the way for a new...